Hemangiosarcoma After Breast-conserving Therapy of Breast Cancer: Report of Four Cases with Molecular Genetic Diagnosis and Literature Review

Carolin Nestle-Kraemling, Edwin Bölke*, Wilfried Budach, Matthias Peiper, Dieter Niederacher, Wolfgang Janni, Claus Ferdinand Eisenberger, Wolfram Trudo Knoefel, Axel Scherer, Stephan Ernst Baldus, Guido Lammering, Peter Arne Gerber, Christiane Matuschek

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Web of Science)


Hemangiosarcomas of the breast represent a rare disease of the breast mainly occurring as secondary neoplasias with a latency of 5-10 years after primary treatment of breast cancer and are associated with an unfavourable prognosis. Radiation therapy, which is integrated within the concept of breast conserving therapy ranks as the main risk factor.In this report we describe the clinical course of 4 patients including their molecular genetic pattern and give a summary of the actual literature.Hemangiosarcomas occur as a secondary neoplasm with a latency of 5-10 years after primary treatment of breast cancer and have an unfavorable prognosis. A genetic predisposition is assumed, but we could not find a significant role of tumor suppressor genes BRCA1, BRCA2 or p53 in our patients.Due to limited data available for these tumors, recommendations for therapy include radical tumor resection achieving wide free margins and inconsistent regimens of chemo- and/or immunetherapy modalities. In the majority these are based on systemic therapy regimens for other cutaneous sarcomas, such as Kaposi's sarcoma. Efforts should be taken for a nation-wide systematic registration of all cases of post-irradiation hemangiosarcomas.
Original languageEnglish
Pages (from-to)656-664
JournalStrahlentherapie Und onkologie
Issue number10
Publication statusPublished - Oct 2011


  • Hemangiosarcoma
  • Breast cancer
  • Secondary neoplasia
  • Breast conserving therapy
  • Radiation therapy
  • TRAM flap

Cite this